Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
T
T
Reiman
K A
KA
Graham
J
J
Wong
A R
AR
Belch
R
R
Coupland
J
J
Young
C E
CE
Cass
J R
JR
Mackey
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D020869:Gene Expression Profiling; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D004248:DNA (Cytosine-5-)-Methyltransferases; D014740:Vidarabine; C024352:fludarabine; D000093542:Gemcitabine